1-(2,6-Difluoro-4-hydroxyphenyl)ethanone | 1378820-19-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2,6-Difluoro-4-hydroxyphenyl)ethanone
• 英文别名: 1-(2,6-difluoro-4-hydroxyphenyl)ethanone
• CAS: 1378820-19-9
• 化学式: C₈H₆F₂O₂
• 分子量: 172.13
• InChiKey: DDEKVGKWWNMZOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• 8-Substituted isoquinoline derivative and the use thereof
  申请人：Kaneko Shunsuke

  公开号：US20100261701A1

  公开（公告）日：2010-10-14

  The present invention relates to a compound represented by the following formula (1): wherein D 1 , A 1 , D 2 , R 1 , D 3 , and R 2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.

  本发明涉及一种由以下式（1）表示的化合物： 其中D1，A1，D2，R1，D3和R2分别具有与本说明书中定义的相同含义或其盐。由式（1）表示的化合物或其盐具有IKKβ抑制活性等，对于预防和/或治疗IKKβ相关疾病或症状等方面是有用的。
• DIACYLETHYLENEDIAMINE COMPOUND
  申请人：Kawano Tomoaki

  公开号：US20120046292A1

  公开（公告）日：2012-02-23

  [Problem] A compound which is useful as an anti-obesity agent is provided. [Means for Solution] The present inventors have investigated a compound having a DGAT1 inhibitory action, which is promising as an active ingredient of a pharmaceutical composition for treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases, and as a result, they have found that the diacylethylenediamine compound of the present invention has an excellent DGAT1 inhibitory action, thereby completing the present invention. That is, the diacylethylenediamine compound of the present invention has a DGAT1 inhibitory action, and can be therefore used as an agent for preventing and/or treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases.

  提供一种作为抗肥胖剂的化合物。现发明人调查了一种具有DGAT1抑制作用的化合物，该化合物有望成为治疗肥胖、2型糖尿病、脂肪肝以及与这些疾病相关的疾病的药物组合物的有效成分，并且他们发现了本发明的二酰乙二胺化合物具有出色的DGAT1抑制作用，从而完成了本发明。也就是说，本发明的二酰乙二胺化合物具有DGAT1抑制作用，因此可用作预防和/或治疗肥胖、2型糖尿病、脂肪肝以及与这些疾病相关的药物。
• 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP2366699A1

  公开（公告）日：2011-09-21

  The present invention relates to a compound represented by the following formula (1): wherein D1, A1, D2, R1, D3, and R2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.

  本发明涉及下式（1）所代表的化合物： 其中 D1、A1、D2、R1、D3 和 R2 各具有与本说明书中定义相同的含义或其盐。式（1）代表的化合物或其盐具有 IKKβ 抑制活性等，可用于预防和/或治疗 IKKβ 相关疾病或症状等。
• POLYURETHANE, POLYURETHANE PRODUCTION METHOD, CONDUCTIVE PASTE COMPOSITION, CONDUCTIVE WIRE, AND METHOD FOR PRODUCING CONDUCTIVE WIRE
  申请人：SHIN-ETSU CHEMICAL CO., LTD.

  公开号：US20220157484A1

  公开（公告）日：2022-05-19

  A polyurethane contains a weakly acidic functional group having a pKa of 5 to 11. Thus, the present invention provides: a conductive paste composition for forming a stretchable conductive wire which varies slightly in electric conductivity at the time of elongation and shrinkage; and a polyurethane for providing the composition.
• US8299055B2
  申请人：——

  公开号：US8299055B2

  公开（公告）日：2012-10-30